
5 Things to Know About Efforts to Curb Antibiotic Resistance
Growing antibiotic resistance is a significant global problem. But steps are being taken to apply brakes on the rise of "superbugs."
It’s a significant problem around the globe—the development of so-called “superbugs,” deadly bacteria that are resistant to treatment with our most common, and, till recently, successful antibiotics. Overprescription, using antibiotics without testing if an individual has a bacterial or a viral infection, and the lack of innovative antibacterial drug development have contributed to this. But steps are being implemented to curb this dangerous development, including the following:
1. At the beginning of this year, 85 biopharmaceutical and diagnostic companies
- Reducing the development of drug resistance
- Increasing investment in research and development that meets global public health needs.
- Improve access to high-quality antibiotics for all
2. Meanwhile, lawmakers in the United States have vowed to take the antibiotic resistance problem very seriously. Earlier this week, at a hearing organized by the House Energy and Commerce Committee's Oversight and Investigations Subcommittee, federal healthcare experts
3. The National Quality Forum (NQF)
4. CMS, on its part, has threatened to
5. Experts believe we need a new business model in the field of antibiotic development—to encourage innovative antibacterial treatments. In an article published in the journal
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.